Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
165.5 USD | -0.40% | -3.40% | -7.98% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 313.47 and 111.8 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.98% | 9.28B | B+ | ||
-3.37% | 186B | C+ | ||
-2.44% | 107B | C | ||
-3.93% | 67.44B | A | ||
+3.07% | 50.03B | B- | ||
+16.42% | 47.81B | B- | ||
+4.79% | 41.03B | B+ | ||
+1.57% | 26.85B | B | ||
+2.94% | 25.82B | A- | ||
-0.38% | 25.01B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RGEN Stock
- Ratings Repligen Corporation